What are the diagnostic criteria and treatment options for autoimmune hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis and Treatment of Autoimmune Hepatitis

The diagnosis of autoimmune hepatitis requires a comprehensive laboratory workup including autoantibody testing, elevated IgG levels, liver biopsy showing interface hepatitis with lymphoplasmacytic infiltrate, and exclusion of other liver diseases, while treatment should be initiated with a combination of prednisone and azathioprine for all patients with moderate to severe inflammation. 1

Diagnostic Criteria

Laboratory Testing

  • Elevated aminotransferases (AST/ALT)
  • Elevated serum IgG/hypergammaglobulinemia
  • Positive autoantibodies:
    • Type 1 AIH (80% of cases): ANA and/or SMA positive
    • Type 2 AIH: Anti-LKM1 and/or anti-LC1 positive
  • Significant titers in adults: ≥1:40 for ANA, SMA, anti-LKM1, and anti-LC1 1
  • Significant titers in children: 1:20 for ANA/SMA and 1:10 for anti-LKM1 1

Histological Features

  • Interface hepatitis (hallmark feature)
  • Predominantly lymphoplasmacytic infiltrate
  • Emperipolesis (lymphocytes within hepatocyte cytoplasm)
  • Hepatocellular rosette formation 1, 2
  • Centrilobular injury may represent early disease 2

Validated Scoring Systems

  • Original Revised Scoring System (1999):
    • Definite AIH: ≥15 points
    • Probable AIH: 10-15 points
  • Simplified Scoring System (2008):
    • Definite AIH: ≥7 points
    • Probable AIH: ≥6 points 1

Exclusion of Other Liver Diseases

Essential to exclude:

  • Viral hepatitis
  • Wilson disease
  • Alpha-1 antitrypsin deficiency
  • Drug-induced liver injury
  • Alcoholic liver disease
  • Non-alcoholic fatty liver disease
  • Primary biliary cholangitis
  • Primary sclerosing cholangitis 1

Treatment Approach

Indications for Treatment

  • All patients with moderate to severe inflammation should receive treatment, including:
    • AST/ALT >5 times upper limit of normal
    • Serum globulins >2 times upper limit of normal
    • Liver biopsy showing confluent necrosis 1
  • Treatment should also be considered in milder cases if:
    • Patient has symptoms
    • Cirrhosis is present on biopsy
    • Patient is younger 1

First-Line Treatment

  • Combination therapy with prednisone and azathioprine is preferred:
    • Prednisone 30 mg/day (tapered over weeks to 10 mg/day or less)
    • Azathioprine 50 mg/day 1
  • This combination results in fewer corticosteroid-related side effects (10% versus 44%) compared to prednisone monotherapy 1
  • Alternative first-line option: prednisone with mycophenolate mofetil 3

Treatment Duration and Monitoring

  • Treatment should be given for at least 3-5 years
  • Continue for at least 2 years after achieving complete biochemical response 3
  • Regular monitoring of transaminases and IgG levels is essential 1
  • Complete biochemical remission defined as normalization of both transaminases and IgG levels 1
  • Consider repeat liver biopsy before withdrawing treatment 1

Special Considerations

Challenging Presentations

  • 10-20% of patients may have insufficient response to standard therapy 1
  • Diagnostic uncertainty may require a trial of steroids with quick tapering in atypical cases 1
  • Differentiation from drug-induced liver injury can be challenging 4

Overlap Syndromes

  • AIH may overlap with primary biliary cholangitis or primary sclerosing cholangitis 1
  • All children with AIH should undergo MR cholangiography to exclude autoimmune sclerosing cholangitis 1
  • Manifestations of bile duct injury require careful evaluation for variant forms 5

Long-term Follow-up

  • Lifelong monitoring in a designated liver clinic is recommended 1
  • Bone mineral densitometry at baseline and annually for patients on long-term corticosteroids 1
  • HCC screening with liver ultrasound every 6 months in cirrhotic patients 1
  • Corticosteroid-related side effects occur in up to 80% of patients after 2 years 1

Common Pitfalls and Caveats

  • Diagnosis may be challenging in cholestatic and severe presentations 4
  • Cirrhosis at presentation occurs in approximately 1/3 of adults and 1/2 of children 1
  • Extra-hepatic autoimmune diseases are common in AIH patients and may require additional management 1
  • Clinical manifestations vary widely, from asymptomatic to fulminant disease 3
  • Autoantibody testing must be performed according to guidelines to be reliable 3

References

Guideline

Autoimmune Hepatitis Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Role of Histopathology in Autoimmune Hepatitis.

Digestive diseases (Basel, Switzerland), 2015

Research

Autoimmune hepatitis - update on clinical management in 2017.

Clinics and research in hepatology and gastroenterology, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.